BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:A2 Biotherapeutics Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies A2 Biotherapeutics Inc.'s drugs r
 un\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05736731-2310@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:A2B530: Phase 1/2 readout est. (NCT05736731)
DESCRIPTION:A2B530\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stud
 y to Evaluate the Safety and Efficacy of A2B530\, a Logic-gated CAR T\, in
  Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Ex
 pression\nEstimated primary completion: December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/a2b530#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05736731
URL:https://assetmemo.bio/drug/a2b530#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06051695-2311@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:A2B543: Phase 1/2 readout est. (NCT06051695)
DESCRIPTION:A2B543\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stud
 y to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated 
 CAR T\, in Participants With Solid Tumors That Express MSLN and Have Lost 
 HLA-A*02 Expression\nEstimated primary completion: June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/a2b543#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06051695
URL:https://assetmemo.bio/drug/a2b543#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06682793-2309@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:A2B395: Phase 1/2 readout est. (NCT06682793)
DESCRIPTION:A2B395\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stud
 y to Evaluate the Safety and Efficacy of A2B395\, an Allogeneic Logic-gate
 d CAR T\, in Participants With Solid Tumors That Express EGFR and Have Los
 t HLA-A*02 Expression\nEstimated primary completion: 31 March 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/a2b395#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06682793
URL:https://assetmemo.bio/drug/a2b395#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
